QGEN
QIAGEN N.V.
Next earnings Aug 3, 2026 (after close) · consensus $0.61 EPS, $539M rev
$40.10
▲ +0.78%$40.10▼ -11.09%
over 1Y
L $32.63H $55.66
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+0.8%
1W+3.0%
1M+12.4%
3M-2.3%
YTD-6.5%
1Y-11.1%
Buy
Conviction
Horizon
Long (>12mo)
Street · 23 analysts
Buy
High-margin molecular-diagnostics franchise with recovering profitability — net income rebounded sharply on a 62% gross margin.
Revenue $2.09B · FY2025
The read
Quality fundamentals and an attractive price line up (~84% below fair value) — the rarer case where both the business and the entry look good.
QIAGEN is a high-quality molecular-diagnostics and sample-technology company with a razor-and-blade consumables model that produces a 62.2% gross margin. FY2025 marked a strong profitability recovery: revenue grew 5.7% to $2.09B while net income jumped to $425M from a depressed $83.6M in FY2024 (which was weighed down by one-time items), with operating income of $466M and EPS of $1.94. The 22.3% operating margin and 20.3% net margin reflect the underlying earnings power once the prior-year charges roll off, and the rebound brings profitability back in line with the company's FY2021-2022 range ($423M-$513M).
The balance sheet remains healthy: $3.78B equity, $839M cash (+26%), and a 50%+ drop in current liabilities, though long-term debt nearly doubled to $1.65B. Capital allocation is shareholder-friendly — $280M of buybacks reduced shares 2.4%, supplemented by a modest dividend. Operating cash flow of $654M comfortably funds the $201M of capacity-expanding capex.
Is QGEN a buy? The one-page verdict, explained →
The options angle
model · matches our verdictBull call spread~90d expiry
- Long call 40 @ ~2.45 est
- Short call 44 @ ~0.96 est
debit $149max +$251max −$149BE 41.49
BUY verdict with defined risk: the short call finances part of the long one; max loss is the net debit.
Educational template, not a trade recommendation. Strikes and premiums are Black-Scholes model estimates from the last close and 30-day realized volatility — real chains, spreads and IV will differ. Options involve substantial risk.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $2.25B | $2.14B | $1.97B | $1.98B | $2.09B |
| Gross profit | $1.45B | $1.38B | $1.23B | $967M | $1.30B |
| Operating income | $630M | $531M | $410M | $97.7M | $466M |
| Net income | $513M | $423M | $341M | $83.6M | $425M |
| Diluted EPS | $2.21 | $1.84 | $1.48 | $0.37 | $1.94 |
| Net margin | 22.8% | 19.8% | 17.4% | 4.2% | 20.3% |
10-year statements — income, cash flow, balance sheet & CSV export →
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$9.09B
EV / EBITDA13.8
EV / Sales4.3
EV / FCF20.0
P / FCF18.2
PEG (trailing)0.05
Earnings yield5.1%
FCF yield5.5%
Quality & risk
ROIC (est.)6.8%
Free cash flow$453M
Total debt$1.65B
Net cash-$815M
Piotroski F-Score7/9
Capital returns
Buyback yield3.4%
Dividend yield (est.)0.7%
Shareholder yield4.0%
Shares Δ YoY-2.4%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Recent filings
all on EDGAR ↗SCHEDULE 13G/AFiling2026-06-05open ↗SDFiling2026-06-01open ↗6-KPeriod ending 2026-03-312026-05-08open ↗6-KPeriod ending 2026-03-312026-05-08open ↗6-KPeriod ending 2026-03-312026-05-01open ↗IRANNOTICEFiling2026-03-20open ↗20-FPeriod ending 2025-12-312026-03-20open ↗SCHEDULE 13G/AFiling2026-02-10open ↗SCHEDULE 13GFiling2026-02-06open ↗6-KPeriod ending 2025-12-312026-02-06open ↗25-NSE/AFiling2026-01-09open ↗25-NSEFiling2026-01-08open ↗
Frequently asked
- Is QIAGEN N.V. (QGEN) a buy?
- QGEN currently carries a Buy rating with 3/5 conviction, derived from its latest SEC filings. High-margin molecular-diagnostics franchise with recovering profitability — net income rebounded sharply on a 62% gross margin.
- What is QGEN's fair value?
- A Modified-Graham model based on QGEN's SEC fundamentals estimates a fair value of about $73.72. It is an estimate from reported earnings, not a price target.
- Is QGEN overvalued or undervalued?
- Against a Modified-Graham fair-value estimate, QGEN currently appears undervalued relative to its SEC-grounded earnings power.
- What is QIAGEN N.V.'s quality score?
- QGEN scores 71.73930527620566/100 (grade B) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001015820, latest SCHEDULE 13G/A filed 2026-06-05) · EODHD · Proprietary analysis · as of 6/21/2026, 8:53:04 PM.
About this recommendation — produced by TENK/calls (tenkcalls.com), Luxembourg · not investment advice
AI-generated analysis, produced by our proprietary engine from SEC filing data.
Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jun 21, 2026, 4:53 PM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.